Stifel Financial Corp lessened its stake in Teladoc Health Inc (NYSE:TDOC) by 7.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 220,377 shares of the health services provider’s stock after selling 16,900 shares during the quarter. Stifel Financial Corp owned approximately 0.30% of Teladoc Health worth $14,965,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Marshall Wace North America L.P. bought a new stake in Teladoc Health in the first quarter valued at approximately $35,000. Cornerstone Advisors Inc. increased its holdings in shares of Teladoc Health by 187.0% during the 2nd quarter. Cornerstone Advisors Inc. now owns 465 shares of the health services provider’s stock worth $31,000 after acquiring an additional 303 shares during the last quarter. Commonwealth Equity Services LLC increased its holdings in shares of Teladoc Health by 9.0% during the 2nd quarter. Commonwealth Equity Services LLC now owns 31,143 shares of the health services provider’s stock worth $2,068,000 after acquiring an additional 2,563 shares during the last quarter. Westside Investment Management Inc. bought a new stake in Teladoc Health in the 2nd quarter valued at $26,000. Finally, Artemis Investment Management LLP raised its stake in Teladoc Health by 4.9% in the 2nd quarter. Artemis Investment Management LLP now owns 151,900 shares of the health services provider’s stock valued at $9,800,000 after acquiring an additional 7,147 shares during the period.
A number of equities analysts have commented on the stock. Zacks Investment Research cut shares of Teladoc Health from a “buy” rating to a “hold” rating and set a $89.00 price objective for the company. in a research report on Wednesday, November 27th. SunTrust Banks reiterated a “hold” rating and issued a $80.00 price objective on shares of Teladoc Health in a report on Monday. Piper Jaffray Companies set a $87.00 price objective on shares of Teladoc Health and gave the company a “buy” rating in a research report on Friday, August 16th. Oppenheimer set a $83.00 target price on shares of Teladoc Health and gave the stock a “buy” rating in a research note on Friday, September 6th. Finally, Stifel Nicolaus started coverage on shares of Teladoc Health in a report on Monday, November 25th. They set a “hold” rating and a $83.00 target price for the company. Four analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of “Buy” and an average target price of $81.73.
In other Teladoc Health news, insider Adam C. Vandervoort sold 50,955 shares of the firm’s stock in a transaction on Thursday, October 31st. The stock was sold at an average price of $75.00, for a total transaction of $3,821,625.00. Following the transaction, the insider now owns 9,769 shares in the company, valued at approximately $732,675. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Adam C. Vandervoort sold 3,525 shares of the firm’s stock in a transaction on Friday, November 8th. The stock was sold at an average price of $79.12, for a total value of $278,898.00. Following the transaction, the insider now owns 1,114 shares in the company, valued at approximately $88,139.68. The disclosure for this sale can be found here. Insiders sold a total of 76,582 shares of company stock valued at $5,614,983 in the last three months. Insiders own 3.14% of the company’s stock.
Shares of Teladoc Health stock opened at $83.74 on Monday. The firm has a 50-day moving average of $75.77 and a 200-day moving average of $66.84. The stock has a market cap of $6.06 billion, a PE ratio of -58.15 and a beta of 1.40. Teladoc Health Inc has a 52-week low of $42.08 and a 52-week high of $86.30. The company has a debt-to-equity ratio of 0.44, a quick ratio of 6.55 and a current ratio of 6.55.
Teladoc Health (NYSE:TDOC) last released its quarterly earnings results on Wednesday, October 30th. The health services provider reported ($0.28) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.40) by $0.12. Teladoc Health had a negative net margin of 20.15% and a negative return on equity of 11.23%. The business had revenue of $137.96 million for the quarter, compared to the consensus estimate of $136.46 million. During the same period in the prior year, the company posted ($0.34) earnings per share. Teladoc Health’s revenue was up 24.3% compared to the same quarter last year. Equities research analysts predict that Teladoc Health Inc will post -1.55 earnings per share for the current fiscal year.
About Teladoc Health
Teladoc Health, Inc provides telehealth services. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone.
Further Reading: Benefits of owning preferred stock
Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.